Approaches for Lynch syndrome screening and characteristics of subtypes with mismatch repair deficiency in patients with colorectal carcinoma
Authors:
Open Access
- 7 August 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 155 (10) , 1780-1791
Abstract
To evaluate different Lynch syndrome (LS) screening approaches and establish an efficient and sensitive strategy are critical for clinical practice. In total, 583 patients with colorectal carcinoma (CRC) at Fudan University Shanghai Cancer Center were enrolled. Patient samples were examined by immunohistochemistry (IHC) and next‐generation sequencing (NGS), and MLH1 promoter hypermethylation (MPH) was detected in MLH1‐deficient cases. Germline genetic testing was performed in cases with deleterious variants and large genomic rearrangements (LGRs) of tumor MMR genes were detected in cases with dMMR or MSI‐H cases with no MMR germline variants. Our results showed that triage with IHC and followed by BRAF/MLH1 methylation testing (Strategy 1) identified 93.3% (70/75) of LS cases. IHC followed by germline NGS (Strategy 2) or direct tumor NGS (Strategy 3) both identified 98.7% (74/75) of LS cases. The proportion of LGRs in LS cases was 16.0% (12/75), while 84.0% (63/75) showed SNV/Indel. The average cost per patient was ¥6010.81, ¥6058.48, and ¥8029.98 for Strategy 1, Strategy 2 and Strategy 3, respectively. The average time spent on different strategies was 4.74 days (Strategy 1), 4.89 days (Strategy 2), and 14.50 days (Strategy 3) per patient, respectively. LS and Lynch‐like syndrome (LLS) were associated with an earlier onset age than MPH. In conclusion, we compared different workflows for LS screening and IHC plus germline NGS is recommended for LS screening when taking sensitivity, time, and cost into account. Moreover, multiplex ligation‐dependent probe amplification made up for the shortcoming of NGS and should be incorporated into routine screening.Keywords
Funding Information
- Science and Technology Commission of Shanghai Municipality (20Z11900300)
- Shanghai Science and Technology Development Foundation (19MC1911000)
- National Natural Science Foundation of China (82103370)
This publication has 31 references indexed in Scilit:
- Distinct clinical phenotype and genetic testing strategy for Lynch syndrome in China based on a large colorectal cancer cohortInternational Journal of Cancer, 2020
- Epidemiological, clinical and molecular characterization of Lynch‐like syndrome: A population‐based studyInternational Journal of Cancer, 2018
- Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular featuresInternational Journal of Cancer, 2018
- Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal CancerJAMA Oncology, 2018
- A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation SequencingThe Journal of Molecular Diagnostics, 2018
- Milestones of Lynch syndrome: 1895–2015Nature Reviews Cancer, 2015
- Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch SyndromeJAMA, 2011
- Mismatch repair deficient colorectal cancer in the era of personalized treatmentNature Reviews Clinical Oncology, 2010
- Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1Nature Genetics, 2008
- The risk of extra‐colonic, extra‐endometrial cancer in the Lynch syndromeInternational Journal of Cancer, 2008